Los Angeles Capital Management LLC Sells 31,270 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Los Angeles Capital Management LLC trimmed its position in Verve Therapeutics, Inc. (NASDAQ:VERV) by 11.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 231,123 shares of the company’s stock after selling 31,270 shares during the period. Los Angeles Capital Management LLC owned 0.27% of Verve Therapeutics worth $1,304,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Creative Planning bought a new position in Verve Therapeutics in the 3rd quarter valued at approximately $50,000. US Bancorp DE increased its position in Verve Therapeutics by 1,631.7% in the 3rd quarter. US Bancorp DE now owns 18,806 shares of the company’s stock valued at $91,000 after acquiring an additional 17,720 shares during the period. Harbor Capital Advisors Inc. raised its stake in shares of Verve Therapeutics by 78.7% during the third quarter. Harbor Capital Advisors Inc. now owns 53,524 shares of the company’s stock valued at $259,000 after acquiring an additional 23,565 shares during the last quarter. Aigen Investment Management LP acquired a new position in shares of Verve Therapeutics during the third quarter worth $74,000. Finally, Accredited Investors Inc. grew its stake in shares of Verve Therapeutics by 14.3% in the third quarter. Accredited Investors Inc. now owns 20,000 shares of the company’s stock worth $97,000 after purchasing an additional 2,500 shares during the last quarter. 97.11% of the stock is currently owned by institutional investors.

Verve Therapeutics Trading Up 2.1 %

VERV stock opened at $6.33 on Friday. The firm has a market cap of $535.92 million, a PE ratio of -2.57 and a beta of 1.74. The stock has a 50-day moving average price of $6.90 and a 200-day moving average price of $6.01. Verve Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The business had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. On average, analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Analysts Set New Price Targets

VERV has been the subject of several analyst reports. Royal Bank of Canada lowered their target price on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright upped their target price on Verve Therapeutics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday. Finally, William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $26.00.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.